Journal of Psychopharmacology
August 27, 2025
Guy A. Higgins, Cam Macmillan, Inés de Lannoy et al.
1 citation
Background and aims: Drug discrimination procedures have made important contributions to the pre-clinical investigation of psychedelic drugs, such as psilocybin, lysergic acid diethylamide (LSD), N,N-dimethyltryptamine (DMT) and 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT). One of the most important being to highlight the critical role of central 5-HT2A receptor agonism as a mediator of...
Molecular Psychiatry
August 26, 2025
Ross J. Purple, Rahul Gupta, Christopher W. Thomas et al.
2 citations
Abstract We quantify cellular- and circuit-resolution neural network dynamics following therapeutically relevant doses of the psychedelic psilocybin. Using chronically implanted Neuropixels probes, we recorded local field potentials (LFP) alongside action potentials from hundreds of neurons spanning infralimbic, prelimbic and cingulate subregions of the medial prefrontal cortex of...
bioRxiv (Cold Spring Harbor Laboratory)
August 22, 2025
Matthew D. Greaves, Tamrin Barta, Leonardo Novelli et al.
preprint
Abstract The extent to which anatomical connectivity constrains pharmacologically altered brain dynamics remains poorly understood. Here, we combined psilocybin administration with a structurally informed effective-connectivity model to examine how structural connectivity shapes directed inter-regional influences across experiential contexts. Using dynamic causal modeling embedded in a...
Neuropharmacology
August 21, 2025
James J Gattuso, Geraldine Kong, Bilgenur Bezcioglu et al.
7 citations
Psilocybin, a serotonergic compound that produces psychedelic effects primarily through activation of the 5-HT2A receptor, has shown promise in treating neuropsychiatric conditions, including obsessive-compulsive disorder (OCD). However, the effects of chronic psilocybin administration on gut function, microbiota, and behavioural phenotypes remain understudied. The present study investigated...
The International Journal of Psychiatry in Medicine
August 20, 2025
Harold G. Koenig
of
Figshare
August 20, 2025
Danielle S. Stolzenberg
preprint
Data files associated with the manuscript titled: Psilocybin during the postpartum period induces long-lasting adverse effects in both mothers and offspring. These files contain the analyses used for each figure of the paper including the supplement. The postpartum stress protocol is included along with all of the raw maternal behavior data. Additional raw data can be found in the manuscript...
Nature Communications
August 19, 2025
Maxwell B. Madden, Chloe Schaefgen, Binita Vedak et al.
4 citations
Through its widespread reciprocal connections with the cerebral cortex, the claustrum is implicated in sleep and waking cortical network states. Yet, basic knowledge of neuromodulation in this structure is lacking. The claustrum is richly innervated by serotonergic fibers, expresses serotonin receptors, and is suggested to play a role in the ability of psilocybin, which is metabolized to the...
medRxiv
August 16, 2025
S. Parker Singleton, Brooke L. Sevchik, Analiese Lahey et al.
preprint
Abstract Importance Depression is a major cause of disability worldwide, motivating substantial interest in psilocybin as a potential treatment. Objective To conduct a systematic review and meta-analysis of psilocybin’s impact on depressive symptoms and provide a living open data resource. Data Sources PubMed, Embase, Scopus, Web of Science, and PsycINFO retrieved by a systematic search up to...
ACS Medicinal Chemistry Letters
August 15, 2025
Robert B. Kargbo
Novel phenalkylamines and tryptamines such as psilocybin demonstrate promising nontraditional pharmacological profiles for treating psychiatric syndromes. Structural modifications yield functional selectivity at 5-HT receptors, mitigating hallucinogenic risk while preserving therapeutic efficacy. This study integrates receptor and behavioral data to support phenalkylamines and psilocybin as...
General Hospital Psychiatry
August 12, 2025
Margaret Ross, Ravi Iyer, M.l. Williams et al.
13 citations
Psilocybin-assisted psychotherapy appears safe and may offer durable relief from depression and anxiety in individuals with a life-threatening illness.